Views sought on NHS cutting Somerset community hospital beds
Dr Marden added there was medical evidence that people recovered faster in the "familiarity of their homes"."We think this is a very exciting opportunity. We're very lucky in Somerset that we have our 13 community hospitals," he said.On average, one person could spend 37 days within a community hospital bed but the same care could be delivered in somebody's own home in just 17 days, according to Dr Marden.However, some people are concerned that reducing the number of community hospital beds would mean people who cannot be treated at home would be sent to general hospitals further away.One former employee at Crewkerne Community Hospital, who wished to remain anonymous, told BBC Radio Somerset being in a general hospital on a large ward did not help recovery in the same way as a smaller community hospital.Dr Marden added: "Of course, there will be people who have to access hospital-based care. Then, our focus should be to get them back into their communities and ideally back into their own bed at home."We've been doing things in a particular way for a long time, but like anything in medicine there's new opportunities. There's things we can do in local communities now that we couldn't have before, like chemotherapies."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
4 minutes ago
- Reuters
Novo Nordisk debuts Wegovy in South Africa as weight-loss drugs race gathers pace
JOHANNESBURG, Aug 14 (Reuters) - Danish drugmaker Novo Nordisk ( opens new tab introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's (LLY.N), opens new tab Mounjaro which launched in the country eight months ago. South Africa has the continent's fourth-highest number of adults with diabetes, according to the International Diabetes Federation, making it a key growth opportunity. "One in two adults right now in South Africa is living with excess weight or obesity," Sara Norcross, general manager of Novo Nordisk South Africa, said at the launch event. "Wegovy is the first and only once-weekly GLP-1 right now that is registered for weight management," she added, referring to a class of therapies known as GLP-1 receptor agonists that make people feel fuller for longer. Novo already sells Ozempic in South Africa for diabetes treatment. Eli Lilly also sells Mounjaro only for the treatment of Type 2 diabetes in South Africa, through Aspen Pharmacare (APNJ.J), opens new tab, though some people take the drug for weight loss. Wegovy, already launched in 35 countries, will be available in five dose strengths in South Africa, and its pricing will be disclosed next week, the company said. Mounjaro, also a once-weekly injectable treatment, is priced from 3,400 rand ($194) for four vials of its lowest dose, depending on the pharmacy or clinic. Novo plans to expand Wegovy into other African markets, Norcross told Reuters, as part of a push to boost sales outside the United States. "I believe it's going to be launching in Egypt soon, and registrations are being submitted for other countries too," she said. The company generates the bulk of its profits from Wegovy sales in the U.S., where it competes with Eli Lilly's Zepbound and Mounjaro. More than a billion people have obesity worldwide, according to the World Health Organization, and around 70% of them live in low and middle-income countries, highlighting the potential impact of weight-loss drugs like Wegovy in underserved markets. In South Africa alone, around 20 million people are overweight or obese, though less than 1% currently receive treatment, Norcross said. The WHO plans to back the use of weight-loss drugs to treat obesity in adults for the first time, Reuters reported in May, signalling a significant shift in the agency's stance on tackling the global health challenge. ($1 = 17.5258 rand)
The Herald Scotland
34 minutes ago
- The Herald Scotland
Mounjaro prices double as weight loss jab popularity soars
A Lilly spokesperson said: 'Following a review, Lilly will increase the UK list price for Mounjaro (tirzepatide) from 1 September to address pricing inconsistencies compared to other developed countries, including in Europe. We have reached an agreement with the NHS to ensure continued supply and patient access." The statement continues: 'While Lilly does not determine the prices that private healthcare providers set, we are working with them to maintain patient access. The UK was one of the first countries where Lilly launched Mounjaro, and our priority was to bring it to patients as quickly as possible during a time of limited supply of GLP-1 RA treatments for type 2 diabetes. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability." More than 1.5 million people in the UK are believed to be using weight-loss medication each month, with most buying the jabs from private pharmacies. Mounjaro users report surprising side effect - pharmacists share their tips — Bucks Free Press (@bucksfreepress) August 8, 2025 This comes as the Government has joined forces with Eli Lilly in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Recommended reading: Mounjaro warning as pens ruined by heatwave temperatures This comes as users are risking having to throw away perfectly good Mounjaro pens as they have overheated in the recent heatwave. Improper storage of Ozempic, Wegovy and Mounjaro during a heatwave could destroy the active ingredient in these jabs, potentially wiping out their effects entirely, even if the medication looks completely normal. 'We recommend treating your weight-loss pen the same way you'd treat insulin or any critical medication,' says Danielle Brightman, Clinical Director at Numan. 'When in doubt, don't risk it. Speak to a healthcare professional and arrange a replacement.' 8 tips to protect Mounjaro and other weight-loss injections during hot weather Use a medical-grade cool bag. Transport your pen in a proper, insulated container designed for sensitive medications. Don't use improvised ice packs that might freeze the pen by accident. Never leave your pen in hot places. Even 10 minutes in a parked car or on a sunny kitchen counter could expose it to damaging heat if out of its delivery packaging or unrefrigerated. Always check the environment before setting it down. Store below 30°C once in use. Once opened and if not refrigerated, keep your pen in a shaded, ventilated area, away from heat sources, windows, and radiators. If you live in a flat or home without air conditioning, keep the pen in a bedroom or hallway that doesn't heat up from direct sun. Avoid storing near exterior walls if the property retains heat. Follow the usage timeline carefully. The storage instructions between medications. Wegovy after first use can last 6 weeks below 30 degrees then needs to be disposed of, whereas Mounjaro has a shorter time of 30 days below 30 degrees before needing to be disposed of. Stick to that timeframe, and if you're unsure whether it's still safe, consult your provider. Use a fridge thermometer at home. Fridge temperatures can fluctuate, especially in older models or over-packed shelves. A simple digital fridge thermometer can help ensure your pen is always stored between 2–8°C before first use. Planning to travel? Use airline-friendly cooling cases. If you're flying or taking long journeys, consider TSA-approved insulated medication pouches with cooling gel packs. Always store the pen in carry-on luggage, not checked baggage, as cargo holds can get hot or cold. Set storage reminders on your phone. If you're prone to forgetting where you left your pen, set daily reminders to check if it's stored properly, especially during heatwaves or while travelling. Don't store near appliances or steam sources. Keep pens away from kettles, toasters, ovens, dishwashers, and anywhere that might experience sudden heat or humidity, especially in small kitchens or shared spaces. Injections like Ozempic, Wegovy, and Mounjaro are now widely used across the UK for appetite control and sustainable weight management. But despite their growing popularity and increasing availability now through the NHS, most patients don't realise the strict temperature guidelines that must be followed to keep these drugs effective. 'We speak to patients every day who are using GLP-1s for the first time,' says Danielle. 'With temperatures set to soar again this summer, it's crucial we raise awareness about safe medication storage. Heat damage isn't always obvious, but it can have a huge impact on effectiveness and safety."
The Independent
an hour ago
- The Independent
Maine clinics hope to get blocked Medicaid funds restored as they sue Trump administration over cuts
A network of clinics that provides health care in Maine is expected to ask a judge Thursday to restore its Medicaid funding while it fights a Trump administration effort to keep federal money from going to abortion providers. President Donald Trump's policy and tax bill, known as the ' big beautiful bill,' blocked Medicaid money from flowing to Planned Parenthood, the nation's largest abortion provider. The parameters in the bill also stopped funding from reaching Maine Family Planning, a much smaller provider that offers health care services in one of the poorest and most rural states in the Northeast. A federal judge ruled last month that Planned Parenthood clinics around the country must continue to be reimbursed for Medicaid funding as the provider wrangles with the Trump administration over efforts to defund it. Maine Family Planning filed a federal lawsuit last month seeking to restore reimbursements. Lawyers and representatives for Maine Family Planning say its 18 clinics provide vital services across the state including cervical cancer screenings, contraception and primary care to low-income residents. They also say the funding cut occurred even though Medicaid dollars are not used for its abortion services. 'Without Medicaid, MFP will be forced to stop providing all primary care for all patients — regardless of their insurance status — by the end of October,' the organization said in a statement, adding that about 8,000 patients receive family planning and primary care from the network. It also said many Maine Family Planning clinics 'provide care in very rural areas of the state where there are no other health care providers, and around 70% of their patients rely exclusively on MFP and will not see any other health care provider in a given year.' In court documents, Anne Marie Costello, deputy director for the Center for Medicaid & CHIP Services, called the request to restore funding 'legally groundless' and said it 'must be firmly rejected.' 'The core of its claim asks this Court to revive an invented constitutional right to abortion — jurisprudence that the Supreme Court decisively interred — and to do so in a dispute over federal funds,' Costello said. While advocates of cutting Medicaid for abortion providers focused on Planned Parenthood, the bill did not mention it by name. Instead it cut off reimbursements for organizations that are primarily engaged in family planning services — which generally include things such as contraception, abortion and pregnancy tests — and received more than $800,000 from Medicaid in 2023. The U.S. Senate's parliamentarian rejected a 2017 effort to defund Planned Parenthood because it was written to exclude all other providers by barring payments only to groups that received more than $350 million a year in Medicaid funds. Maine Family Planning asserts in its legal challenge that the threshold was lowered to $800,000 this time around to make sure Planned Parenthood would not be the only entity affected. It is the only other organization that has come forward publicly to say its funding is at risk. Planned Parenthood's legal fight with the Trump administration over Medicaid funding is still in the court system also.
